NEWS FEATURE

‘Business of science’ digest—December 2020

COVID vaccine news dominates our last monthly round-up of articles from Springer Nature research journals, magazines and supplements of the year. The articles explore how the many vaccines in development are affecting the pharmaceutical sector and what challenges lie ahead for their rollout.
Raveena obtained her bachelor's degree in biochemistry from the University of Leeds, UK. She has worked in the biopharma industry for more than 15 years, focusing on dealmaking, partnering and licensing throughout. In her first role, Raveena started as an editorial assistant, moving on to become content editor, specifically involved with conducting partner searches to identify both products/technologies and partners for pharmaceutical clients. She then worked for a biopharma reports publisher, editing and writing dealmaking-focused reports. In 2015 Raveena became the editor of Biopharma Dealmakers.

Search for this author in:

COVID-19 vaccines buoy hope

Barely a year since the emergence of the SARS-CoV-2 virus, multiple vaccine developers are poised to secure emergency authorization in the USA and the EU.

Nature Reviews Drug Discovery

Divvying up COVID vaccines

Many people in low-income countries might have to wait until 2023 or 2024 for COVID vaccination, according to estimates from the Duke Global Health Innovation Center in Durham, North Carolina. But which country currently leads the pack in terms of doses secured per capita?

Nature

The COVID vaccine challenges that lie ahead

Not making the vaccine affordable for the world’s poorest countries would be morally wrong and short-sighted, argues a Nature editorial, because, as infectious-disease researchers often say, “an outbreak anywhere is an outbreak everywhere.”

Nature

A vaccine dilemma

Emergency COVID-19 vaccine authorisations could complicate subsequent trials as developers face pressure to offer the immunization to participants who received a placebo, jeopardising data collection around long-term outcomes and safety. “It’s a real vaccine-development dilemma,” warns Klaus Stöhr, retired head of vaccine design at Novartis.

Nature

One week, two vaccine trial results

On November 13, two days after Pfizer and BioNTech announced positive interim results from its coronavirus vaccine phase 3 trial, the developers of a controversial Russian Sputnik V vaccine announced its candidate seems to be similarly effective at preventing the disease.

Nature

India’s COVID drugs approvals questioned

The Drugs Controller General of India (DCGI) has approved several repurposed drugs for ‘restricted emergency use’ for treating the disease, but some scientists are questioning the basis for the approval.

Nature

How COVID-19 affected pharmaceutical external innovation sourcing

The disruptive impact of the pandemic on the pharmaceutical sector has been multifaceted, given the industry’s role in delivering innovations to address it. This 5-year analysis of R&D deals also looks at how the innovation sourcing landscape may evolve.

Nature Reviews Drug Discovery

Calling all young European biomedical researchers

The Eppendorf Young Investigator Award is granted annually to European researchers not older than 35 years and acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts. The winner is selected by an independent expert committee. Applications are open until 16th January 2021. Apply now.

Award

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.